Originally published In Press as doi:10.1074/jbc.M001719200 on April 11, 2000
J. Biol. Chem., Vol. 275, Issue 29, 21905-21913, July 21, 2000
Characterization and Functional Significance of Calcium
Transients in the 2-Cell Mouse Embryo Induced by an Autocrine Growth
Factor*
Michael
Emerson
§¶,
Angela R.
Travis
§¶,
Roslyn
Bathgate
§,
Tomas
Stojanov
§,
David I.
Cook§,
Elizabeth
Harding§,
David P.
Lu
, and
Christopher
O'Neill
§
From the
Human Reproduction Unit,
§ Department of Physiology, University of Sydney, Royal
North Shore Hospital,
St. Leonards, New South Wales 2065, Australia
Received for publication, March 2, 2000, and in revised form, April 10, 2000
 |
ABSTRACT |
Growth of preimplantation embryos is
influenced by autocrine trophic factors that need to act by the 2-cell
stage, but their mode of action is not yet described. This report shows
that late zygote and 2-cell stage mouse embryos responded to
embryo-derived platelet-activating factor (PAF) with transient
increases in intracellular calcium concentration
([Ca2+]i). [Ca2+]i
transients were single global events and were specifically induced by
embryo-derived PAF. They were blocked by inhibition of phospholipase C
(U 73122) and an inositol trisphosphate (IP3) receptor
antagonist (xestospongin C), indicating the release of calcium from
IP3-sensitive intracellular stores. Transients were also
inhibited by the absence of calcium from extracellular medium and
partially inhibited by treatment with dihydropyridine (nifedipine, 10 µM), but not pimozide (an inhibitor of an embryonic
T-type calcium channel). (±)BAY K8644 (an L-type channel agonist)
induced [Ca2+]i transients, yet these were
completely inhibited by nifedipine (10 µM). The complete
inhibition of BAY K8644, but only partial inhibition of PAF by
nifedipine shows that L-type channels were only partly responsible for
the calcium influx. Depolarization of 2-cell embryos by 50 mM K+ did not inhibit PAF-induced calcium
transients, showing that the influx channels were not
voltage-dependent. Depletion of intracellular calcium
stores by thapsigargin revealed the presence of store-operated channels. The interdependent requirement for IP3-sensitive
internal calcium stores and extracellular calcium in the generation of PAF-induced transients may be explained by a requirement for
capacitative calcium entry via store-operated channels. A functionally
important role for the PAF-induced transients is supported by the
observation that inhibition of [Ca2+]i transients
by a PAF-antagonist (WEB 2086) or an intracellular calcium chelator
(1,2-bis(2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid tetrakis-acetoxymethyl ester; BAPTA-AM) caused marked inhibition of early embryo development. Growth inhibition by BAPTA-AM was relieved
by addition of exogenous PAF.
 |
INTRODUCTION |
The cells of the mammalian preimplantation embryo (from the time
of fertilization until the implantation of the blastocyst into the
uterus) form the progenitor cells for all other cell lineages. The
regulation of the growth and survival of the cells of the early embryo
is, however, poorly understood. Mammalian preimplantation embryos
develop in vitro with simple medium requirements and have no
absolute requirement for exogenous vitamins, hormones, or growth
factors. This contrasts with the absolute requirement of normal somatic
cells for exogenous mitogens and survival factors. The continued
mitoses of preimplantation embryo cells in the absence of exogenous
growth factors implicates a role for endogenous, autocrine trophic
factors, or the constitutive activation of signaling pathways in the
early embryo. Several lines of evidence support a role for the former:
(i) the rate of embryo development in vitro is
density-dependent, with embryos growing in relatively small volumes (or in large groups) developing more successfully than those
grown in large volumes (or individually) (1, 2); (ii) the synthesis by
the preimplantation embryo of a number of growth factor ligands and
their receptors (3-8); and (iii) the capacity of some exogenous growth
factors to enhance embryo metabolism in vitro and to
compensate for the adverse effects of culture in large medium volumes
(1, 2, 9).
Experimental partial deprivation of released autocrine trophic factors
did not arrest the cell-cycle at given checkpoints (9). Rather, there
was progressive loss of viability with increased cell death as embryos
progressed past the 8-cell stage. This finding suggests that the
autocrine factors may act as survival factors rather than classical
growth factors (triggering progression through specific cell-cycle
checkpoints). While several autocrine factors have been implicated,
platelet-activating factor
(PAF)1 seems to be one of the
first produced, being synthesized de novo by the embryo soon
after fertilization (10, 11). Its actions are required by the
mid-2-cell stage for normal rates of embryo survival (9).
Despite this range of supportive data, there is limited direct evidence
for the action of autocrine trophic factors in early embryo
development. Transgenic and recombinant knock-out models have not
generally been informative of the growth requirements of the early
embryo prior to implantation. This may be due to extensive redundancy
of regulatory pathways.
Growth/survival factors exert their effects by generating secondary
messengers that then exert downstream actions. The generation of
transient increases in intracellular free calcium concentrations ([Ca2+]i) is a universally important secondary
messenger (12). [Ca2+]i transients are known to
be important regulators of the early embryo's developmental program.
The fertilizing sperm induces a series of calcium transients in oocytes
that cause oocyte activation and have longer term consequences for
normal embryo development (13-16). A [Ca2+]i
transient also occurs at the time of nuclear envelope breakdown in the
mouse zygote (17). The post-fertilization calcium oscillations and the
transients associated with nuclear envelope breakdown require factor(s)
derived from the sperm that become associated with the nuclear
membrane. There is no direct evidence of a developmental requirement
for calcium transients in the mammalian early embryo outside these
defined periods, although evidence that induction of artificial
transients in morulae enhanced the rate of blastocyst formation (18,
19) and the inhibition of embryo development by a calmodulin antagonist
(W-7) suggests a role (20). It was recently shown (21) that exogenous
PAF may induce calcium transients in the 2-cell mouse embryo although a
mechanism for this action was not defined, nor was it established whether embryo-derived PAF also induced such responses.
The aims of the study were, therefore, to screen preimplantation stage
mouse embryos for evidence of [Ca2+]i transients;
to define the causative agent of any transient observed; to provide
characterization of the [Ca2+]i transients; and
to assess whether their induction had developmental consequences for
the early embryo. We found that embryo-derived PAF caused transients in
late zygotes and 2-cell embryos during interphase and that they were
necessary for normal rates of embryo development in
vitro.
 |
MATERIALS AND METHODS |
Animals--
Female Swiss albino mice (Laboratory Animal
Services, University of Sydney, NSW, Australia), 6-9 weeks old, were
superovulated by intraperitoneal injection of 10 IU of equine chorionic
gonadotropin (eCG, Folligon, Intervet International, Boxmeer, The
Netherlands) followed 48 h later by 10 IU of human chorionic
gonadotropin (Chorulon, Intervet). Females were then left unmated or
paired with males of proven fertility. Fertilization occurred by
13 h after human chorionic gonadotropin. Day 1 of pregnancy was
confirmed by the presence of a copulation plug. The use of animals was
in accordance with the Australian Code of Practice for the Care and Use
of Animals for Scientific Purposes, and was approved by the
Institutional Animal Care and Ethics Committee.
Collection Medium and Embryo Collection--
All components of
medium were tissue culture grade from Sigma. Unless otherwise stated
all media were supplemented with 3 mg of BSA/ml (Fraction V, CSL Ltd.,
Melbourne, Victoria, Australia).
Mice were killed by cervical dislocation. Embryos or cumulus masses
were flushed from the reproductive tract using Hepes-buffered modified
human tubal fluid medium (Hepes-modHTF (1)) with 3 mg of BSA/ml.
Zygotes and oocytes were freed from their cumulus cells by brief
exposure to 300 IU of hyaluronidase (Sigma). Embryos fertilized in the
reproductive tract were collected by dissection from the ampulla region
of the oviduct. Zygotes and embryos that were not immediately prepared
for calcium imaging were cultured in bicarbonate-buffered modified HTF
medium (modHTF) (1) containing 3 mg of BSA/ml at 37 °C, 5%
CO2 in air.
Calcium Imaging--
Calcium imaging was performed with embryos
mounted in a chamber on a microscope coverslip. The chamber contained
~0.5 ml of medium and was perfused with medium at 37 °C at a rate
of 1 ml/min. Perfusion medium was the same composition as Hepes-modHTF
with 3 mg of BSA/ml, but without phenol red.
Embryos were washed 3 times in Hepes-modHTF and incubated with Fura-2
AM (2 µM; Molecular Probes, Eugene, OR) in BSA-free perfusion medium for 30 min and then washed 3 times in BSA-free perfusion medium. In some experiments embryos were then incubated in
recombinant plasma-type PAF acetylhydrolase (rPAF acetylhydrolase, 174 µg/ml; ICOS Inc., Bothell, WA) (22) in BSA-free perfusion medium for
15 min and washed in BSA-free perfusion medium before calcium imaging.
The perfusion chamber was constructed from perspex (40 × 70 × 5 mm, width × length × depth) into which an elliptical
slot was created. The slot was sealed at the base with a glass
coverslip (with high vacuum silicon grease, Ajax Labs., Auburn, NSW,
Australia). The slot held approximately 0.5 ml of medium. The top of
the slot was open and medium was added at the rate of 1 ml/min, at one end of the slot and removed at the far end. Fluid was pumped through the chamber by a variable speed peristaltic pump.
Embryos in BSA-free perfusion medium were placed onto a
Cell-TakTM (Collaborative Biomedical Products, Bedford,
MA)-treated glass coverslip that was attached to the perfusion chamber.
After establishing baseline readings and subtracting background
readings, perfusion was initiated. Relative changes in intracellular
calcium concentration were measured using fluorescence ratiometric
imaging of Fura-2 at excitation wavelengths of 340 and 380 nm. One
frame (0.04 s) was captured at each wavelength every 15 s. The
[Ca2+]i is the average over an entire cell
(zygote-8-cell stage) or an entire embryo (morulae) and thus may not
reflect the peak calcium concentrations achieved within regions of a
cell. Results were recorded with a Panasonic video camera (model WV-BP 310/A) linked to a Macintosh computer via a Pixelpipeline frame grabber. Images were captured and analyzed with IonvisionTM
software (Improvision, Coventry, UK). All imaging was performed on a
Nikon Diaphot microscope using 100 W Xenon illumination, and a ×20
Olympus DPlan Apo UV lens. Up to 10 embryos were within the field of
view of this objective and were imaged simultaneously.
Calibration Procedure for Measuring Intracellular Calcium
Concentration--
Intracellular calcium concentrations were
calculated using the equations of Grynkiewicz et al. (23).
Rmax (340/380 nm ratio value at high calcium
concentrations) was determined in the presence of 2 mM
calcium and ionomycin (1 µM, Calbiochem, Alexandria, NSW, Australia). Rmin (340/380 nm ratio value in
calcium-free conditions) was determined by perfusing with
Ca2+-free perfusion medium until a stable baseline was achieved.
Treatments--
The effect of the following exogenous growth
factors was tested: EGF (human recombinant EGF, Sigma, lot 63HD04135),
insulin-like growth factor 1 (human recombinant insulin-like growth
factor 1, Sigma, lot 83H09655), transforming growth factor-
(porcine platelet transforming growth factor-
, R&D Systems Inc., MN, lot 1085); platelet-derived growth factor (human platelet-derived growth
factor, R&D Systems Inc., lot D711); and PAF (Sigma, equal mixture of
1-O-octadecyl/hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine). EGF, insulin-like growth factor-1, transforming growth factor-
, and
platelet-derived growth factor were first dissolved in 0.01 M acetic acid, freeze dried, and then brought to working
concentrations in perfusion medium. PAF was prepared as a 10 mg/ml
stock solution in chloroform. Aliquots were removed to a siliconized
glass test tube, reduced to dryness under a stream of N2,
and dissolved in perfusion medium to the desired concentration.
Some inhibitors and antagonists were also used. WEB 2086 (a competitive
PAF-receptor antagonist, a gift of Boeringher Ingelheim AG, Ingelheim,
Germany) was dissolved in perfusion medium. A stock solution of BN
50730 (PAF antagonist, a gift of Institute Henri Beaufour, Paris,
France) was prepared in Me2SO. Working solutions were
prepared by dilution in perfusion medium to give a final Me2SO concentration less than 0.2% (v/v). BAPTA-AM (0.1 and 0.5 µM; Sigma) was prepared in Hepes-modHTF. Embryos
were exposed to BAPTA-AM for 20 min washed and then added to the
perfusion chamber. In some cases, BAPTA-AM-treated embryos (0.5 or 1 µM; for 20 min at 27 h post-fertilization; early
2-cell stage) were set up in culture in modHTF, either untreated or
supplemented with 20 ng of PAF/ml, and development monitored each
24 h for 96 h.
To determine the dependence of transients on extracellular calcium,
responses to embryo-derived PAF or exogenous PAF were examined in
perfusion medium free of calcium (with osmolality adjusted with NaCl).
The role of calcium channels was assessed by the inhibitory action of
nifedipine (Calbiochem, L-type channel blocker) or pimozide (Sigma,
T-type channel blocker). The presence of a functional L-type calcium
channel was confirmed by challenging 2-cell embryos with mixed
enantiomer (±)BAY K8644 (Sigma) which has a net agonistic action on
calcium channels. Internal stores of calcium were depleted by use of
the calcium-ATPase inhibitor, thapsigargin (1 µM, Sigma).
It was prepared in BSA-free medium and embryos were treated with
thapsigargin for 15 min prior to PAF challenge. The action of
phospholipase C (PLC) in generating the intracellular
[Ca2+]i transient was measured by treating 2-cell
embryos with U73122 (5 µM, Calbiochem) for 5 min prior to
challenge with exogenous PAF (37.2 nM). Challenge of
untreated embryos and embryos treated with U73343 (Calbiochem; an
inactive analogue of U73122) acted as controls. A cell-permeable
inositol trisphosphate (IP3)-receptor antagonist,
xestospongin C (24) (Calbiochem), was prepared as a stock solution in
ethanol and then diluted in perfusion medium to working concentration
of 10 µM. Embryos were incubated with xestospongin (for
30 min immediately prior to challenge with PAF). Some zygotes were
cultured in
-amanitin (11 µg/ml, Sigma) from 5 h
post-fertilization to assess the role of transcription of new mRNA
in the onset of the embryo responsiveness to PAF.
Cell Counts--
Cell counts were performed by visualization of
cell nuclei following staining with 4 µg/ml Hoechst dye 33342 (bisbenzimide, Sigma). Embryos were left in this solution for 45-60
min and then prepared as wet mounts on a glass microscope slide under a coverslip.
Statistical Analysis--
An embryo was considered to have
responded with a [Ca2+]i transient if the
[Ca2+]i increased to be greater than twice the
standard deviation of the average baseline ratio within 5 min of
perfusion commencing and then subsequently decreased. A minimum of 5 readings was obtained for baseline assessment. Data is expressed as the
mean ± S.E. of the [Ca2+]i at each
observation time for all embryos, or as traces of individual embryos.
Statistical analyses were performed on SPSS statistical package
(version 8, SPSS Inc., Chicago, IL). Dichotomous outcomes were analyzed
by Chi-squared analysis. Responses over time were analyzed by repeated
measures analysis of variance. Comparisons of peak amplitude of calcium
responses or time taken to achieve peak amplitudes were by t test.
 |
RESULTS |
Spontaneous [Ca2+]i Transients Occurred
in 2-Cell Embryos but Required Albumin in the Extracellular
Medium--
A surprising initial observation was that 2-cell embryos
often displayed a spontaneous [Ca2+]i transient
soon after imaging commenced without other treatment. This only
occurred if embryos were collected and prepared in protein-free
conditions and then exposed to medium containing albumin during
imaging; in the absence of albumin from perfusion medium,
[Ca2+]i transients were not seen (Fig.
1a). This calcium response was
consistently observed as a single global calcium transient throughout
the entire cell (zygote), or in both cells of the 2-cell embryo.
Repetitive oscillations over the time frame of observation (30 min)
were not detected. The transients were not artifactual responses to
changes in temperature or osmolality since these potential variables
were carefully controlled.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 1.
The change of [Ca2+]i
was assessed in 2-cell embryos. a, when the embryos were in
medium containing albumin ( , n = 50) or in
protein-free medium ( , n = 50). b,
pretreated with rPAF acetylhydrolase (174 µg/ml, ,
n = 55) or vehicle control ( , n = 53), before perfusion of the chamber with albumin containing medium.
The results are the mean and S.E. of (n) embryos per
treatment.
|
|
The loading of embryos with Fura-2 AM, their subsequent washing and
set-up on the imaging slide were all performed in protein-free medium.
The response to medium containing albumin may indicate that albumin
itself acted as a signaling molecule, or that it acted as an acceptor
for a released embryo-derived trophic molecule. Albumin is required for
the release of PAF from cells (25), including the 2-cell embryo (26,
27), so we tested the hypothesis that PAF accumulates on the embryo's
outer plasma membrane during processing in protein-free medium and is
released upon exposure to albumin. This was done by determining whether
the embryos response to albumin was inhibited by treating the embryos
with exogenous rPAF acetylhydrolase (degrading PAF to an inactive form)
prior to exposure to albumin. After Fura-2 AM loading, embryos were incubated with 174 µg of rPAF acetylhydrolase or vehicle for 15 min.
They were then washed and challenged with perfusion medium containing
BSA (Fig. 1b). The rPAF acetylhydrolase treatment inhibited (p < 0.001) calcium transients in response to perfusion.
Spontaneous Calcium Transients Are Caused by Embryo-derived
PAF--
The inhibition of spontaneous transients after rPAF
acetylhydrolase treatment suggests that PAF was the only agent
responsible for inducing these transients. To determine whether other
embryonic growth factors might also cause calcium transients, a range
of peptide growth factors was added as exogenous components of medium: EGF (1-1000 ng/ml), insulin-like growth factor-1 (1-1000 ng/ml), platelet-derived growth factor (0.1-2.5 ng/ml), and transforming growth factor-
(0.1-10 ng/ml). None of these induced any observable change in [Ca2+]i (results not shown).
Following embryo-derived PAF-induced [Ca2+]i
transients in 2-cell embryos, the same embryos failed to show any
response to an immediate further challenge with exogenous PAF (results not shown) suggesting desensitization/down-regulation of the response. Down-regulation of an initial response to exogenous PAF (372 nM) also occurred; rPAF acetylhydrolase-treated embryos
were exposed to exogenous PAF for 5 min and then at various intervals a
second PAF challenge was applied. No embryos showed a
[Ca2+]i response to the second PAF challenge at
15 or 25 min after the first challenge. By 35 min a small number (17%)
responded and the proportion responding further increased at 40 min
(75%) and 75 min (79%) (75 min results are shown in Fig.
2).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2.
The response of individual 2-cell embryos
pretreated with rPAF acetylhydrolase and then challenged with exogenous
PAF (372 nM) for 5 min. This was followed
by washout with perfusion medium and then challenged with a second PAF
treatment at 75 min. Arrows show the times of PAF
challenge.
|
|
The Response of Embryos to PAF Was Specific and
Receptor-dependent--
To enable the characterization of
the action of PAF-antagonists on PAF-induced
[Ca2+]i transients in 2-cell embryos, it was
necessary to standardize the concentration of the PAF challenge. This
was achieved by degrading externalized embryo-derived PAF with rPAF
acetylhydrolase followed by exposure of embryos to exogenous PAF.
Embryos (collected 29-31 h post-fertilization) responded to PAF
(0.037-372 nM) in a dose-dependent manner
(Fig. 3). At the lowest concentrations (0.037 nM) responses were not common and were of low
amplitude when they did occur. At a concentration of 0.37 nM, low amplitude (p < 0.01) transients
were consistently observed. At a concentration of 3.7, 37.2 (results
not shown), and 372 nM responses were of a consistently
high amplitude. At 0.37 nM, the time taken for the peak
amplitude of the response to be achieved was longer (p < 0.01) compared with higher doses. Transients in response to exogenous PAF were typically single peaks; repetitive oscillations of
short duration were rarely observed. The new baseline established after
the [Ca2+]i peak was generally higher than the
original baseline, perhaps indicating residual capacitative calcium
entry (CCE).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 3.
The change in [Ca2+]i
in 2-cell embryos (29-31 h post-human chorionic gonadotropin) in
response to increasing concentration of exogenous PAF:
0.037 nM ( , n = 32), 0.37 nM ( , n = 37), 3.7 nM
( , n = 50), and 372 nM ( ,
n = 54).
|
|
WEB 2086 (0.44-44 µM), a competitive PAF-receptor
antagonist (28), reduced the mean amplitude of
[Ca2+]i transients in response to exogenous PAF
(37 nM) compared with control responses. Responses were
reduced (p < 0.0001) at 0.4-4.4 µM
(Table I) and essentially abolished at 44 µM. BN 50730 also caused partial inhibition
(p < 0.001) of [Ca2+]i
transients induced by PAF but was not as effective as WEB 2086 (Table
I).
View this table:
[in this window]
[in a new window]
|
Table I
The effect of PAF-receptor antagonists on PAF-induced calcium
transients in 2-cell embryos
The results are the mean ± S.E. of three replicates with at least
8 embryos per replicate. Statistical analysis is in the text.
|
|
The specificity of PAF's action was further confirmed by testing the
response of embryos to the enantiomeric isomer of PAF (3-O-alkyl-2-acetyl-sn-glycero-1-phosphocholine).
Over a concentration range of 40-400 nM, enantiomeric PAF
was without effect on the [Ca2+]i of 2-cell
embryos (35-37 h) that had been pretreated with rPAF acetylhydrolase
(results not shown).
The Ontogeny of Responsiveness to PAF--
Unfertilized oocytes
and young zygotes (7-9 h after fertilization) failed to show any
[Ca2+]i transients in response to medium
containing albumin. By 10-13 h after fertilization, 8 of 32 zygotes
showed detectable [Ca2+]i transients, and these
were of modest amplitude (87.8 ± 24.5 nM above
baseline values).
For 2-cell embryos collected fresh from the reproductive tract,
transients in response to embryo-derived PAF varied with the age of the
embryo (Fig. 4a). At 27-29 h
after fertilization there were modest responses to embryo-derived PAF.
By 31-33 h after fertilization the average
[Ca2+]i transient was significantly
(p < 0.01) greater in peak amplitude above baseline
and reached its peak earlier (p < 0.01) than observed
at 27-29 h. At 35-37 h embryo responses to embryo-derived PAF had
declined in average amplitude (p < 0.01) and took
longer (p < 0.05) to achieve peak amplitude above
baseline than observed at 31-33 h. By 41-43 h the responses were
significantly (p < 0.05) attenuated compared with each
other time point tested for 2-cell embryos. No
[Ca2+]i transients were observed in 4-cell,
8-cell, and morulae stage embryos (not shown).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 4.
a, the [Ca2+]i
response of 2-cell embryos to embryo-derived PAF. Embryos were
collected and tested at 27-29 h (n = 48), 31-33 h
(n = 57), 35-37 h (n = 48), and 41-43
h (n = 27) after fertilization. The results are the
mean ± S.E. of the number (n) of embryos shown.
b, calcium transients induced by exogenous PAF (372 nM). 2-Cell embryos were collected fresh from the
reproductive tract, treated with rPAF acetylhydrolase to degrade
embryo-derived PAF and then challenged with exogenous PAF. The
responses were from cohorts of embryos collected at different times
during the 2-cell stage of development as indicated: 27-29 h
(n = 34), 31-33 h (n = 61), 35-37 h
(n = 54), and 41-43 h (n = 37) after
fertilization. The results are the mean ± S.E. of the number
(n) of embryos shown.
|
|
To determine whether these changes in responsiveness during development
were due to changes in the availability of embryo-derived PAF or to
changes in the capability of embryos to respond to PAF, we compared the
embryo-derived PAF induced [Ca2+]i responses to
those induced by exogenous PAF (372 nM) (in rPAF
acetylhydrolase treated embryos). Oocytes and early embryos (7-9 h
after fertilization) did not respond to exogenous PAF, but by 10-13 h
after fertilization embryos showed a [Ca2+]i
response. The peak amplitude of the response to exogenous PAF was
significantly (p < 0.0001) larger (157.1 ± 16.4 nM above baseline) than the embryo-derived PAF-induced responses.
In 2-cell embryos the [Ca2+]i response to
exogenous PAF was greater than the spontaneous responses at each of the
times studied (Fig. 4b). In contrast to spontaneous
[Ca2+]i transients, the amplitude of the response
to exogenous PAF was similar (p > 0.05) at 27-29 h
and 31-33 h after fertilization. Transients were significantly
attenuated at 35-37 and 41-43 h after fertilization
(p < 0.01) compared with younger 2-cell embryos. At
each of these times, the average amplitude of response to exogenous PAF
was greater than the response to embryo-derived PAF in corresponding embryos. Only 4 of 38 4-cell embryos showed modest but variable [Ca2+]i transients (47.3 ± 22.9 nM [Ca2+]i above baseline;
n = 4), and no 8-cell embryos displayed a response to
exogenous PAF (n = 37).
The greater amplitude of responses to exogenous PAF in late zygotes and
27-29-h-old 2-cells shows that embryo-derived PAF may be limiting at
those times. The failure of early zygotes to respond to either source
of PAF shows that they were not capable of responding at that time.
Furthermore, the similar loss of responsiveness to both forms of PAF in
the late 2- and 4-cell embryo shows that this was also not primarily
due to a lack of embryo-derived PAF.
The Onset of Responses to PAF Requires Transcription from the
Zygotic Genome--
To define the time of onset of responsiveness more
precisely, zygotes were collected from the reproductive tract
approximately 5 h after fertilization and cultured in
vitro. They were treated with rPAF acetylhydrolase and then
challenged with exogenous PAF at 10, 11, and 12 h after
fertilization and the [Ca2+]i response monitored.
At 10 h, consistent but relatively low amplitude responses were
observed (Fig. 5). The average amplitude of the responses increased (p < 0.01) with each
subsequent hour of culture (11 and 12 h post-fertilization). When
zygotes were cultured in
-amanitin for the same periods, the
[Ca2+]i response to PAF was significantly
inhibited (p < 0.0001) at all time points (the
inhibition of the response by
-amanitin at 12 h after
fertilization is shown in Fig. 5). Therefore, the onset of
[Ca2+]i transients in response to exogenous PAF
first occurred from 10 h after fertilization and required a
transcriptional event.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5.
The calcium response in zygotes collected
5 h after fertilization, cultured in vitro and
tested at 10 h ( , n = 39), 11 h ( ,
n = 39) and 12 h ( , n = 39)
after fertilization. Some embryos ( , n = 44)
were cultured after fertilization in -amanitin and tested at 12 h after fertilization. The results are the mean ± S.E. of the
number of embryos indicated.
|
|
PAF-induced Calcium Transients Required Extracellular and
Intracellular Calcium--
A role for internal calcium stores was
implicated by inhibition of PAF-induced responses by the inhibition of
PLC by U73122 (5 µM, 5 min) while its inactive analogue
(U73343, 5 µM, 5 min) was without effect (Fig.
6). It seems likely that the action of PLC was to produce IP3 since the cell-permeable
IP3-receptor antagonist (Xestospongin C, 10 µM, 30 min) also inhibited PAF-induced transients (Fig.
6).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 6.
The effect of phospholipase C inhibition and
antagonism of IP3-receptors on exogenous PAF-induced
calcium transients in the 2-cell embryo. Traces show: the response
of control embryos to exogenous PAF (37.2 nM); the effect
of treatment of embryos with the phospholipase C inhibitor U73122 (5 µM); the effect of U73343, being an inactive analogue of
U73122; and the effect of xestospongin C (10 µM). Each
panel shows a typical response. Each treatment was performed 3 times
with 6-8 embryos per replicate. Embryos were treated with U73122 and
U73343 for 5 min and xestospongin for 30 min prior to PAF challenge.
The arrow shows the time of PAF challenge.
|
|
A role for extracellular calcium in generating the response was also
implicated by the failure of 2-cell embryos to respond to PAF in
calcium-free medium (Fig. 7). This was
the case for both embryo-derived and exogenous PAF. The addition of
EGTA (Fig. 7) to calcium-free medium caused a
[Ca2+]i transient even in the absence of PAF,
illustrating an unexpected aspect of calcium homeostasis in the early
embryo that requires further investigation.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of extracellular calcium on
PAF-induced calcium transients in 2-cell embryos. Traces show: the
response to albumin containing medium; the response to embryo-derived
PAF1 in medium with calcium replaced with NaCl; the response of 2-cell
embryos treated with rPAF acetylhydrolase and then challenged with 20 ng of PAF/ml in calcium-free medium; and response of rPAF
acetylhydrolase-treated 2-cell embryos to calcium-free medium with EGTA
(2 mM), but without PAF. Each trace represents a typical
response from three replicates with 6-8 embryos per replicate.
|
|
Treatment of 2-cell embryos with a dihydropyridine (nifedipine, 10 µM) significantly (p < 0.001) inhibited
PAF-induced calcium transients (Fig. 8),
suggesting the involvement of a dihydropyridine-sensitive calcium
channel in generating the rise in [Ca2+]i. BAY
K8644 induced calcium transients in a dose-dependent manner
confirming the presence of a functional L-type calcium channel in the
2-cell embryo (Fig. 9). However, the
[Ca2+]i transient induced by BAY K8644 was
entirely inhibited by 10 µM nifedipine (Fig. 9),
indicating that the calcium influx induced by PAF was not entirely
accounted for by the L-type channel. The 2-cell embryo also possesses a
T-type (low voltage-activated) channel that is inhibited by pimozide
(29). However, pimozide had no influence (p > 0.05) on
PAF-induced [Ca2+]i transients (results not
shown) suggesting that the T-channel was not involved in this response.
Depolarization of 2-cell embryos by perfusing with 25 or 50 mM K+ for 5 min (perfusion media had NaCl
isomotically replaced with KCl) did not induce
[Ca2+]i transients or changes in the baseline
calcium levels (not shown). In the presence of 50 mM
K+ 2-cell embryos still showed characteristic transients to
embryo-derived PAF, however, the amplitude of the responses was
consistently lower than responses in control media (Fig.
10). This result shows that the
PAF-induced calcium influx was not voltage-gated, but as expected the
rate and extent of calcium influx was influenced by the membrane
potential.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 8.
The effect of nifedipine on exogenous
PAF-induced calcium transients. The results are the mean of four
replicates with 6-8 embryos per replicate. The arrow
represents the time of initiation of PAF challenge.
|
|

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 9.
The effect of (±)BAY K8644 on
[Ca2+]i in PAF acetylhydrolase-treated 2-cell
embryos over the concentration range 1-100
µM. The results are the
mean of three replicates with 6-8 embryos per replicate.
|
|

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 10.
The effects of membrane depolarization by 50 mM KCl on [Ca2+rsqb]i transients
induced by embryo-derived PAF in 2-cell embryos. KCl replaced NaCl
to maintain osmotic pressure of the media. Perfusion was commenced with
50 mM KCl containing 3 mg/ml BSA/ml to induce the
transient. The experiment was replaced 3 times with at least 8 embryos
per replicate. The results are representative traces for each
treatment.
|
|
The activation of store-operated calcium channels (SOC) in
non-excitable cells is induced by release of calcium from
IP3-sensitive stores (30). Experimental activation of SOCs
can be achieved by depletion of internal calcium stores by
thapsigargin. Treatment of 2-cell embryos with thapsigargin (1 µM) caused a characteristic transient of similar
magnitude as that caused by PAF (Fig.
11). Continued treatment with
thapsigargin resulted in a new baseline being established that was
consistently higher than the pretreatment baseline. In the absence of
extracellular calcium, thapsigargin treatment still caused a
characteristic transient but the [Ca2+]i then
declined to below original baseline (Fig. 11). The establishment of a
new higher baseline in medium containing calcium after thapsigargin
treatment is indicative of SOC activity, and consequent CCE.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 11.
The effect on [Ca2+]i
of exposure of 2-cell embryos to thapsigargin (1 µM) in normal perfusion medium (2 mM calcium) and in calcium-free medium. Embryos were
pretreated with rPAF acetylhydrolase and perfusion media was BSA-free.
The results are the mean ± S.E. of 10 embryos.
|
|
PAF-induced Calcium Transients in the Early Embryo Influence Their
Subsequent Developmental Potential--
Buffering intracellular
calcium by treatment of embryos for 20 min with 1 µM
BAPTA-AM caused significant inhibition (p < 0.001) of
embryo-derived PAF-induced-[Ca2+]i transients
(Fig. 12). Following BAPTA-AM
treatment, however, the addition of exogenous PAF was capable of
inducing transients with an amplitude that was significantly greater
(p < 0.001) than those in response to embryo-derived
PAF in the presence of BAPTA-AM, and similar to those induced by
embryo-derived PAF in control embryos (in the absence of BAPTA-AM)
(Fig. 12). Exposure of 2-cell embryos to 1.0 µM BAPTA-AM
for 20 min followed by their culture in vitro, caused a
significant (p < 0.01) reduction in the proportion of
embryos developing to the 4-cell stage and then on to the blastocyst
stage (Table II). Increasing the culture time to 120 h did not increase the number of embryos developing to
the blastocyst stage (not shown). The addition of exogenous PAF to
medium partially ameliorated the actions of BAPTA-AM. At the 4-cell and
8-cell stage, the presence of exogenous PAF prevented the inhibition of
development below control rates (p > 0.05). By the
morulae and blastocysts stage, however, some inhibitory effects were
also manifested by BAPTA-AM-treated embryos exposed to PAF. The rate of
cell-cycle progression throughout the preimplantation phase as assessed
by the number of cells/blastocyst was markedly retarded
(p < 0.01) by the brief exposure to BAPTA-AM at the
two-cell stage. This was significantly reversed by the presence of
exogenous PAF. The results showed that short-term buffering of
intracellular calcium with BAPTA-AM caused long-term adverse effects on
normal embryo development. A significant component of the adverse
effects of BAPTA-AM was due to the inhibition of PAF-induced
transients, since supplementation of medium with PAF could partially
alleviate the consequences of BAPTA-AM treatment.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 12.
The results show traces of: embryo-derived
[Ca2+]i transients; embryo-derived PAF responses
following treatment of embryos with 1 µM BAPTA-AM; and responses of 2-cell
embryos to exogenous PAF (37.2 nM) by 1 µM BAPTA-AM-treated embryos. The
results are the mean of three replicates with 6-8 embryos per
treatment.
|
|
The effect of the PAF-antagonists WEB 2086 and BN 50730 on the
development of zygotes in vitro was assessed (Table
III). Zygotes were cultured singly in
10-µl drops of modHTF under oil for 96 h and the proportion that
developed to the blastocyst stage was assessed. WEB 2086 (44 µM) significantly (p < 0.001) reduced
the proportion of zygotes that developed to the blastocyst stage and the number of cells within each of the resulting blastocysts. The
antagonist did not block zygote to 2-cell progression but caused
progressive loss of viability with development, much as results from
PAF deprivation (9). BN 50730 (4.4 and 44 µM) had no
adverse effect on the development of zygotes to the blastocyst stage,
consistent with its lower effectiveness at blocking PAF-induced [Ca2+]i transients. The development of embryos
collected at the late 2-cell stage (34 h after fertilization) to the
blastocyst stage was unaffected by WEB 2086 (44 µM).
 |
DISCUSSION |
This study showed that embryo-derived PAF induces transient
increases in the [Ca2+]i in the late zygote and
2-cell mouse embryo in vitro. These
[Ca2+]i transients were not apparently associated
with specific cell-cycle checkpoints but occurred during interphase of
the cell-cycle. The induction of these [Ca2+]i
transients was important for normal embryo development since buffering
intracellular calcium concentration with BAPTA-AM inhibited development
and this could be partially alleviated by exogenous PAF. A
concentration of a PAF-antagonist (WEB 2086) that inhibited
[Ca2+]i transients also limited embryo growth.
The specificity of the action of PAF in inducing
[Ca2+]i transients was shown by: (a)
its concentration dependence; (b) the homologous
desensitization of the response by repeated exposure to PAF;
(c) its inhibition by a selective PAF-receptor antagonist;
(d) the failure of the enantiomeric isomer of PAF to elicit
[Ca2+]i responses; (e) the inhibition
of spontaneous transients by exposure of embryos to rPAF
acetylhydrolase; and (f) the failure of a range of other
growth factors to elicit [Ca2+]i transients.
The onset of responsiveness of zygotes to PAF required a
transcriptional event that was inhibited by
-amanitin. It will be of
interest to determine whether this transcription is of a PAF-receptor or an essential component of the transduction pathway. We believe these
[Ca2+]i transients to be the earliest description
of a functional response by the embryo that is dependent upon
transcription from the zygotic genome. It will therefore be an
important tool for investigating the regulatory processes controlling
the onset of transcription from the zygotic genome.
By comparing the embryo's responses to embryo-derived and exogenous
PAF, it was possible to define whether [Ca2+]i
transients were limited by the availability of embryo-derived PAF or
the capability of the embryo to respond to the available PAF. From the
time of onset of the embryo's responsiveness to PAF until 31-33 h
after fertilization the magnitude of transients was limited primarily
by the availability of embryo-derived PAF. After this time the response
became progressively attenuated due to limitations in the capability of
embryos to respond to the available PAF. By the 4- and 8-cell stages,
embryos were generally not capable of responding with
[Ca2+]i transients to either embryo-derived PAF
or exogenous PAF. This ontogeny of responsiveness to PAF is
interesting, since it was previously shown (9) that exposure of embryos
to PAF was required by the mid-2-cell stage. If PAF was limited up to that time (by culturing at low embryo densities), increased rates of
embryonic lethality resulted, but embryos could be rescued by addition
of PAF to medium by the 2-cell stage. Exposure to PAF after the 2-cell
stage was unable to rescue PAF-deprived embryos (9).
The results of the current study provide evidence that the
[Ca2+]i transients required both extracellular
calcium and release of intracellular stores of calcium. The need for
extracellular calcium was supported by the requirement for
extracellular calcium and the partial dihydropyridine (nifedipine)
sensitivity of the PAF-induced transients. The presence of a functional
dihydropyridine-sensitive L-type channel was confirmed by the action of
BAY K8644 in inducing [Ca2+]i transients. We
believe this is the first functional evidence for this channel in the
mammalian 2-cell embryo. Yet, transients induced by BAY K8644 were
entirely inhibited by nifedipine which contrasts with its partial
inhibition of PAF-induced transients. The observation of transients in
2-cells in response to PAF following their exposure to 50 mM K+ suggests that voltage-gated channels were
not a major component of the calcium influx. The inhibition of the
transients by U73122 implicates a role for phosphatidylinositol
4,5-bisphosphate PLC, suggesting mobilization of inositol
trisphosphate-sensitive intracellular stores. An alternative indirect
route of activation via the actions of diacylglycerol (another product
of PLC action) is excluded by the inhibition of the transient by an
IP3-receptor antagonist (xestospongin C).
The observations of a requirement for extracellular calcium and the
involvement of IP3-sensitive stores in intracellular
calcium suggests an interdependence of these two sources of calcium.
Mobilization of internal calcium stores by the PLC/IP3
pathway is widely implicated in the opening of store-operated channels
to initiate CCE (30). Rises in intracellular calcium resulting from
this mechanisms are more sustained, resulting in prolonged elevation
compared with the transients observed in excitable cells, and this is
the pattern observed in PAF-induced embryos. These sustained elevations of intracellular calcium are important in non-excitable cells, and are
known to regulate many cellular processes including new gene
transcription (31, 32). The observation that PAF-induced calcium
transient caused a new, higher baseline calcium concentration to be set
suggests the operation of CCE. The presence of SOCs in the 2-cell
embryo was confirmed by the embryos response to calcium depletion by
thapsigargin. Many different channels have been implicated in CCE,
having differences in ion selectivity, regulation, and pharmacological
properties. The full characterization of the SOCs in the 2-cell embryo
was beyond the scope of this study.
The presence of SOCs and the demonstrated interdependence of internal
and external pools of calcium for the generation of a
[Ca2+]i suggests that a probable mechanism for
the PAF-induced transients may be the receptor activation of PLC that
in turn caused release of IP3-sensitive internal stores.
The activation of SOCs and the resulting CCE secondary to the release
of internal calcium stores may account for the dominant component of
the rise in [Ca2+]i induced by PAF.
In the current study the release of internal calcium stores was not
directly observed in medium free of calcium but can be inferred from
the inhibition of PAF-induced transients by U73122 and xestospongin C. A failure to directly observe them may be due to the sensitivity of the
imaging setup. Whole embryos were recorded as a single image and this
would have the effect of underestimating localized peak changes in
[Ca2+]i. Consequently, small changes
in [Ca2+]i due to release from internal stores
may not have been detected with this setup. The activation of SOCs by
IP3-sensitive stores may occur via the release of a
retrograde soluble messenger from internal stores (33, 34) and/or the
conformational coupling of SOCs with the IP3 receptor (35,
36), however, the mechanisms of regulation still require full elucidation.
The action of externalization of embryo-derived PAF in generating
[Ca2+]i transients is demonstrated by the albumin
dependence of the response and by the inhibition of embryo-derived
PAF-induced responses by exposure of embryos to rPAF acetylhydrolase.
The rapid action of the enzyme, together with its normal location as an
extracellular enzyme (22), indicates that the active embryo-derived PAF
was located on the outer plasma membrane. Mobilization of this PAF to
elicit the calcium response was dependent upon extracellular protein.
This is consistent with previous observations that albumin has high
affinity binding sites for PAF (37), being located on domain II of
albumin (27), and that extracellular albumin was essential for the
release of PAF from the 2-cell embryo (26, 27). Since PAF is a
phospholipid it is hydrophobic, only readily entering the aqueous phase
by binding to a hydrophilic carrier such as albumin. The released
embryo-derived PAF would then be available to interact with PAF
receptors, as demonstrated by the inhibitory action of a PAF-receptor
antagonist, WEB 2086. This hypothetical mechanism provides the basis
for an autocrine loop.
The homologous desensitization of the embryos response to a second PAF
challenge by both embryo-derived and exogenous-PAF may ensure that the
persistent presence of PAF in the embryos vicinity does not cause
chronic elevation of [Ca2+]i. The incidence of
[Ca2+]i transients may therefore be regulated by
both the rate of PAF synthesis/release by the embryo and the rate at
which the embryo becomes resensitized after a PAF-induced response. This model provides a mechanism whereby intermittent
[Ca2+]i transients could occur during the late
zygote and 2-cell stage. Such intermittent calcium transients could
provide an information-rich mechanism for signaling. The observation
that exogenous PAF also induced [Ca2+]i
transients confirms an earlier observation (21). In our hands, however,
responses to exogenous PAF were not regularly observed if prior
treatment with rPAF acetylhydrolase was not used. This seems to be due
to embryo responses to PAF being down-regulated by homologous
desensitization for long periods. The preparation of embryos in
protein-free medium or with rPAF acetylhydrolase was required to allow
them to escape this down-regulation, and to thus consistently detect
PAF-induced transients.
Inhibition of long-term embryo development by exposure of 2-cell
embryos during early interphase to BAPTA-AM for a brief period (20 min)
is consistent with a hypothesis that PAF-induced
[Ca2+]i transients at the 2-cell stage act to
initiate a developmental program. However, buffering cell
cycle-dependent [Ca2+]i transients
can block mitosis (17). In this study the limited exposure to BAPTA-AM
model and the ability of exogenous PAF to reverse its effects argue
that a major cause of the growth restriction caused by BAPTA-AM
treatment was a consequence of inhibiting embryo-derived PAF calcium
transients. A functionally significant role for PAF-induced calcium
transients is further supported by the reduction of embryo development
induced by the PAF-antagonist WEB 2086 at concentrations that inhibited
calcium transients. Another antagonist, BN 50730 was relatively
ineffective in blocking PAF-induced [Ca2+]i and
it had no apparent affect on development.
The findings of: (a) the occurrence of PAF-induced calcium
transients in the early embryo; (b) their inhibition by
buffering intracellular calcium with BAPTA-AM, leading to retarded
embryo development; (c) the partial relief of this
inhibition by excess exogenous PAF; and (d) the correlation
between the inhibition of [Ca2+]i transients by a
PAF antagonist and its inhibition of embryo development; together argue
that mobilization of calcium transients by embryo-derived PAF form an
important autocrine signaling pathway in the zygote and 2-cell embryo
that is required for the subsequent normal rates of development of the
early preimplantation embryo in vitro.
 |
ACKNOWLEDGEMENTS |
We thank M. Moore and H. Kavadias for
undertaking some preliminary experiments, Prof. D. Allen for technical
advice with calcium imaging, K. O'Neill for preparation of the
manuscript, Boeringher Ingelheim AG, Ingelheim, Germany, and the
Institute Henri Beaufour, Paris, France, for the gift of PAF
antagonists, and Dr. L. Tjoekler, ICOS Corp., Seattle, WA, for the gift
of recombinant PAF acetylhydrolase.
 |
FOOTNOTES |
*
This work was supported by grants from the Northern Sydney
Area Health Service, University of Sydney Faculty of Medicine, and New
South Wales Government Employees Health Fund.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Contribututed equally to the results of this work.
To whom correspondence should be addressed. Tel.:
61-2-9926-7148; Fax: 61-2-9926-6343; E-mail:
chriso@med.usyd.edu.au.
Published, JBC Papers in Press, April 11, 2000, DOI 10.1074/jbc.M001719200
 |
ABBREVIATIONS |
The abbreviations used are:
PAF, platelet-activating factor;
BAPTA-AM, 1,2-bis(2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic
acid tetrakis (acetoxymethyl ester;
[Ca2+]i, intracellular calcium
concentration;
modHTF, modified human tubal fluid;
Hepes-modHTF, Hepes-buffered modified human tubal fluid;
IP3, inositol
trisphosphate;
PLC, phospholipase C;
BSA, bovine serum albumin;
EGF, epidermal growth factor;
CCE, capacitative calcium entry;
SOC, store-operated calcium channels.
 |
REFERENCES |
| 1.
|
O'Neill, C.
(1997)
Biol. Reprod.
56,
229-237
|
| 2.
|
Paria, B. C.,
and Dey, S. K.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
4756-4760
|
| 3.
|
Pantaleon, M.,
and Kaye, P. L.
(1996)
Mol. Reprod. Dev.
44,
71-76
|
| 4.
|
Pantaleon, M.,
Whiteside, E. J.,
Harvey, M. B.,
Barnard, R. T.,
Waters, M. J.,
and Kaye, P. L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
5125-5130
|
| 5.
|
Rappolee, R. A.,
Brenner, C. A.,
Schultz, R.,
Mark, D.,
and Werb, Z.
(1988)
Science
241,
1823-1825
|
| 6.
|
Rappolee, D. A.,
Sturm, K. S.,
and Schultz, G. A.
(1990)
in
Early Embryo Development and Paracrine Relationships
(Heyner, S.
, and Wiley, L. M., eds)
, pp. 11-25, Alan R. Liss, New York
|
| 7.
|
O'Neill, C.
(1985)
J. Reprod. Fertil.
75,
375-380
|
| 8.
|
Stojanov, T.,
and O'Neill, C.
(1999)
Biol. Reprod.
60,
674-682
|
| 9.
|
O'Neill, C.
(1998)
Biol. Reprod.
58,
1303-1309
|
| 10.
|
Wells, X. E.,
and O'Neill, C.
(1994)
J. Reprod. Fertil.
101,
385-391
|
| 11.
|
Wells, X. E.,
and O'Neill, C.
(1992)
J. Reprod. Fertil.
96,
61-71
|
| 12.
|
Whitaker, M.,
and Patel, R.
(1990)
Development
108,
525-542
|
| 13.
|
Cheek, T. R.,
McGuinness, O. M.,
Vincent, C.,
Moreton, R. B.,
Berridge, M. J.,
and Johnson, M. H.
(1993)
Development
119,
179-189
|
| 14.
|
Parrington, J.,
Swann, K.,
Shevchenko, V. I.,
Sesay, A. K.,
and Lai, F. A.
(1996)
Nature
379,
364-368
|
| 15.
|
Swann, K.
(1990)
Development
110,
1295-1302
|
| 16.
|
Swann, K.
(1992)
Biochem. J.
287,
79-84
|
| 17.
|
Kono, T.,
Jones, K. T.,
Bos-Mikich, A.,
Whittingham, D. G.,
and Carroll, J.
(1996)
J. Cell Biol.
132,
915-923
|
| 18.
|
Stachecki, J. J.,
Yelian, F. D.,
Schultz, J. F.,
Leach, R. E.,
and Armant, D.
(1994)
Biol. Reprod.
50,
1-9
|
| 19.
|
Stachecki, J. J.,
and Armant, D. R.
(1996)
Development
122,
2485-2496
|
| 20.
|
Poueymitou, W. T.,
and Schultz, R. M.
(1990)
Mol. Reprod. Develop.
26,
211-216
|
| 21.
|
Roudebush, W. E.,
LaMarche, M. D.,
Levine, A. S.,
Jiang, H.,
and Butler, W. J.
(1997)
Biol. Reprod.
57,
575-579
|
| 22.
|
Tjoelker, L. W.,
Wilder, C.,
Eberhardt, C.,
Stafforini, D. M.,
Dietsch, G.,
Schimpf, B.,
Hooper, S.,
Trong, H. L.,
Cousens, L. S.,
Zimmerman, G. A.,
Yamada, Y.,
McIntyre, T. M.,
Prescott, S. M.,
and Gray, P. W.
(1995)
Nature
374,
549-553
|
| 23.
|
Grynkiewicz, G.,
Poenie, M.,
and Tsien, R. Y.
(1985)
J. Biol. Chem.
260,
3440-3450
|
| 24.
|
Gafni, J.
(1997)
Neuron
19,
723-733
|
| 25.
|
Ludwig, J. C.,
Hoppens, C. L.,
McManus, L. M.,
Mott, G. E.,
and Pinckard, R. N.
(1985)
Arch. Biochem. Biophys.
241,
337-347
|
| 26.
|
Ammit, A. J.,
and O'Neill, C.
(1997)
J. Reprod. Fertil.
109,
309-318
|
| 27.
|
Ammit, A. J.,
and O'Neill, C.
(1997)
J. Biol. Chem.
272,
18772-18778
|
| 28.
|
Korth, R.,
Hirafuji, M.,
Keraly, C. L.,
Delautier, D.,
Bidault, J.,
and Benveniste, J.
(1989)
Br. J. Pharmacol.
98,
653-661
|
| 29.
|
Day, M. L.,
Johnson, M. H.,
and Cook, D. I.
(1998)
Pflugers Arch. Eur. J. Physiol.
436,
834-842
|
| 30.
|
Putney, J. W., Jr.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
14669-14671
|
| 31.
|
Berridge, M. J.
(1995)
Biochem. J.
312,
1-11
|
| 32.
|
Golovina, V. A.
(1999)
Am. J. Physiol.
277,
C343-C349
|
| 33.
|
Parekh, A. B.,
and Penner, R.
(1997)
Physiol. Rev.
77,
901-930
|
| 34.
|
Thomas, D.,
Kim, H. Y.,
and Hanley, M. R.
(1998)
Vitam. Horm.
54,
97-119
|
| 35.
|
Kiselyov, K.,
Xu, X.,
Mozhayeva, G.,
Kuo, T.,
Pessah, I.,
Mignery, G.,
Zhu, X.,
Birnbaumer, L.,
and Muallem, S.
(1998)
Nature
396,
478-482
|
| 36.
|
Peterson, C. C. H.,
and Berridge, M. J.
(1996)
Eur. J. Physiol.
432,
286-292
|
| 37.
|
Clay, K. L.,
Johnson, C.,
and Henson, P.
(1990)
Biochim. Biophys. Acta
1046,
309-314
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles: